These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36449662)

  • 1. Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.
    Mishra A; Kumar D; Gupta K; Lofland G; Sharma AK; Banka DS; Hobbs RF; Dannals RF; Rowe SP; Gabrielson E; Nimmagadda S
    Clin Cancer Res; 2023 Feb; 29(3):581-591. PubMed ID: 36449662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.
    Kumar D; Mishra A; Lisok A; Kureshi R; Shelake S; Plyku D; Sen R; Doucet M; De Silva RA; Mease RC; Forde PM; Jaffee EM; Desai P; Ganguly S; Gabrielson E; Vaidya D; Spangler JB; Nimmagadda S
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34508005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive Positron Emission Tomography Imaging of PD-L1 Expression in Human Breast and Lung Carcinoma Xenografts Using the Radiometalated Peptide Ga-68-TRAP-WL12.
    Quigley NG; Steiger K; Färber SF; Richter F; Weichert W; Notni J
    Mol Pharm; 2024 Apr; 21(4):1827-1837. PubMed ID: 38291706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
    Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
    Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
    Kumar D; Lisok A; Dahmane E; McCoy M; Shelake S; Chatterjee S; Allaj V; Sysa-Shah P; Wharram B; Lesniak WG; Tully E; Gabrielson E; Jaffee EM; Poirier JT; Rudin CM; Gobburu JV; Pomper MG; Nimmagadda S
    J Clin Invest; 2019 Feb; 129(2):616-630. PubMed ID: 30457978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Small Cyclic Peptide-Based
    Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of small-molecular-based radiotracers for PET imaging of PD-L1 expression and guiding the PD-L1 therapeutics.
    Yang H; Zeng X; Liu J; Wen X; Liu H; Liang Y; Wang X; Fang J; Zhang Q; Li J; Zhang X; Guo Z
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1582-1592. PubMed ID: 38246910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-PET imaging of
    Liu Q; Jiang L; Li K; Li H; Lv G; Lin J; Qiu L
    Cancer Immunol Immunother; 2021 Jun; 70(6):1721-1733. PubMed ID: 33386467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression.
    Zhang L; Zhang S; Wu W; Wang X; Shen J; Wang D; Hu K; Zhang MR; Wang F; Wang R
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36806629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Zhou M; Xiang S; Zhao Y; Tang Y; Yang J; Yin X; Tian J; Hu S; Du Y
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):369-379. PubMed ID: 37759096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-Based
    De Silva RA; Kumar D; Lisok A; Chatterjee S; Wharram B; Venkateswara Rao K; Mease R; Dannals RF; Pomper MG; Nimmagadda S
    Mol Pharm; 2018 Sep; 15(9):3946-3952. PubMed ID: 30037229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical development of novel PD-L1 tracers and first-in-human study of [
    Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo positron emission tomography imaging for PD-L1 expression in cancer using aptamer.
    Choi YJ; Park JY; Cho YL; Chae JR; Cho H; Kang WJ
    Biochem Biophys Res Commun; 2022 Sep; 620():105-112. PubMed ID: 35780578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
    Jagoda EM; Vasalatiy O; Basuli F; Opina ACL; Williams MR; Wong K; Lane KC; Adler S; Ton AT; Szajek LP; Xu B; Butcher D; Edmondson EF; Swenson RE; Greiner J; Gulley J; Eary J; Choyke PL
    Mol Imaging; 2019; 18():1536012119829986. PubMed ID: 31044647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
    Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
    J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
    Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
    J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer.
    Kong S; Liu Q; Chen Y; Liang B; Zhou Y; Lin J; Xie M; Qiu L
    Mol Pharm; 2024 Jan; 21(1):255-266. PubMed ID: 38093483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
    Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
    Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.